Subclinical BPH in Dogs: The Hidden Challenge in Veterinary Practice

Subclinical benign prostatic hyperplasia (BPH) represents a significant yet often overlooked challenge in veterinary practice. A large proportion of dogs affected by BPH do not exhibit obvious clinical signs, making early detection difficult. Studies have shown that the prevalence of subclinical prostatic disorders can be remarkably high, emphasizing the importance of routine screening in at-risk populations¹. 

Epidemiology and Risk Factors 

BPH is predominantly an age-related condition, with the mean age of affected dogs reported to be around 10 years. It is most commonly observed in intact males, with nearly all cases occurring in noncastrated dogs, highlighting the central role of testosterone in disease pathogenesis². 

Larger breeds appear to be more frequently affected, although the condition can occur across all sizes and breeds. The strong association between hormonal imbalance and prostatic growth underscores the need for regular evaluation in aging intact male dogs. 

Clinical Presentation: Subtle Indicators 

Although most cases are asymptomatic, some dogs may exhibit subtle clinical signs that are easily overlooked. These may include intermittent bloody discharge from the prepuce, mild tenesmus, or slight changes in fecal consistency due to rectal compression by the enlarged prostate^1,3. 

In some cases, reproductive changes such as hemospermia or reduced semen quality may be the only indicators of underlying prostatic disease. These subtle signs highlight the importance of maintaining a high index of suspicion, particularly in breeding animals¹. 

Screening and Early Detection 

Routine screening plays a crucial role in identifying subclinical BPH. Digital rectal examination can detect changes in prostate size and symmetry, even in the absence of clinical signs¹. However, its sensitivity is limited, especially in early or mild cases. 

Ultrasonography provides a more detailed evaluation, allowing visualization of structural changes such as increased size, heterogeneous echotexture, and cystic alterations within the prostate⁴. These findings often precede the development of clinical symptoms, making ultrasound an essential tool for early diagnosis. 

Serum CPSE measurement has emerged as a valuable adjunct in screening for subclinical BPH. Elevated CPSE levels have been associated with increased prostate size and ultrasonographic abnormalities, even in asymptomatic dogs. Combining CPSE analysis with imaging techniques enhances diagnostic accuracy and facilitates early intervention¹. 

Clinical Significance of Early Diagnosis 

Early detection of subclinical BPH is important not only for preventing disease progression but also for preserving reproductive function in breeding dogs. Studies have shown that larger prostate size is associated with a higher likelihood of developing clinical signs over time, highlighting the prognostic value of early screening⁵. 

Furthermore, identifying BPH in its early stages allows for timely implementation of monitoring or therapeutic strategies, reducing the risk of complications such as severe constipation or perineal hernia. 

Management Approach 

Not all cases of subclinical BPH require immediate treatment. In many instances, a conservative approach involving regular monitoring of prostate size, CPSE levels, and clinical status may be sufficient. Treatment is generally indicated when clinical signs develop, when there is significant prostatic enlargement, or when reproductive performance is affected¹. 

Conclusion 

Subclinical BPH represents a common yet underdiagnosed condition in dogs. Its silent nature necessitates a proactive approach to screening and early detection, particularly in aging intact males. By integrating routine clinical examination with ultrasonography and CPSE measurement, veterinarians can identify affected dogs at an early stage and implement appropriate management strategies, ultimately improving long-term outcomes. 

References: 

1. Derakhshandeh N, Mogheiseh A, Nazifi S. Diagnosis and Treatment of Benign Prostatic Hyperplasia in Dogs: New Approaches. Veterinary medicine international. 2025;2025(1):4153172. https://onlinelibrary.wiley.com/doi/pdf/10.1155/vmi/4153172 

2. G. Cazzuli, G. Suarez, S. Busconi, J. P. Dami ´ an, and P. Pessina, ´ “Clinical Signs Associated With Prostatic Disorders in Canines: Retrospective Study in Uruguay (2011–2019),” Open Veterinary Journal 13, no. 10 (2023): 1308–1317. https://www.ajol.info/index.php/ovj/article/download/259402/244946 

3. M. R. Das, R. C. Patra, R. K. Das, P. K. Rath, and B. P. Mishra, “Hemato-Biochemical Alterations and Urinalysis in Dogs Sufering From Benign Prostatic Hyperplasia,” Veterinary World 10, no. 3 (2017): 331–335. https://pmc.ncbi.nlm.nih.gov/articles/PMC5387661/pdf/VetWorld-10-331.pdf 

4. T. Laurusevicius, J. ˇ Siug ˇ zdait ˇ e, N. Juod ˙ ziukynien ˇ e, et al., ˙ “Comparative Evaluation of Diagnostic Methods for Subclinical Benign Prostatic Hyperplasia in Intact Breeding Male Dogs,” Animals 14, no. 8 (2024). https://www.mdpi.com/2076-2615/14/8/1204 

5. D. Pinheiro, J. Machado, C. Viegas, et al., “Evaluation of Biomarker Canine-Prostate Specifc Arginine Esterase (CPSE) for the Diagnosis of Benign Prostatic Hyperplasia,” BMC Veterinary Research 13 (2017): 76–77. https://link.springer.com/content/pdf/10.1186/s12917-017-0996-5.pdf